RSF1 requires CEBP/β and hSNF2H to promote IL-1β-mediated angiogenesis: the clinical and therapeutic relevance of RSF1 overexpression and amplification in myxofibrosarcomas
- 26 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Angiogenesis
- Vol. 24 (3), 533-548
- https://doi.org/10.1007/s10456-020-09764-4
Abstract
Myxofibrosarcoma is genetically complex and lacks effective nonsurgical treatment strategies; thus, elucidation of novel molecular drivers is urgently needed. Reanalyzing public myxofibrosarcoma datasets, we identified mRNA upregulation and recurrent gain of RSF1 and characterized this chromatin remodeling gene. Myxofibrosarcoma cell lines were employed to elucidate the oncogenic mechanisms of RSF1 by genetic manipulation and two IL-1β-neutralizing antibodies (RD24, P2D7KK), highlighting the regulatory basis and targetability of downstream IL-1β-mediated angiogenesis. Tumor samples were assessed for RSF1, IL-1β, and microvascular density (MVD) by immunohistochemistry and for RSF1 gene status by FISH. In vivo, RSF1-silenced and P2D7KK-treated xenografts were analyzed for tumor-promoting effects and the IL-1β-linked therapeutic relevance of RSF1, respectively. In vitro, RSF1 overexpression promoted invasive and angiogenic phenotypes with a stronger proangiogenic effect. RT-PCR profiling identified IL1B as a top-ranking candidate upregulated by RSF1. RSF1 required hSNF2H and CEBP/β to cotransactivate the IL1B promoter, which increased the IL1B mRNA level, IL-1β secretion and angiogenic capacity. Angiogenesis induced by RSF1-upregulated IL-1β was counteracted by IL1B knockdown and both IL-1β-neutralizing antibodies. Clinically, RSF1 overexpression was highly associated with RSF1 amplification, IL-1β overexpression, increased MVD and higher grades (all P ≤ 0.01) and independently predicted shorter disease-specific survival (P = 0.019, hazard ratio: 4.556). In vivo, both RSF1 knockdown and anti-IL-1β P2D7KK (200 μg twice weekly) enabled significant growth inhibition and devascularization in xenografts. In conclusion, RSF1 overexpression, partly attributable to RSF1 amplification, contributes a novel proangiogenic function by partnering with CEBP/β to cotransactivate IL1B, highlighting its prognostic, pathogenetic, and therapeutic relevance in myxofibrosarcomas.Keywords
Funding Information
- Ministry of Science and Technology (108-2320-B-182A-017-MY3)
This publication has 46 references indexed in Scilit:
- ASS1as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic RelevanceClinical Cancer Research, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Human CCAAT/Enhancer-Binding Protein β Interacts with Chromatin Remodeling Complexes of the Imitation Switch SubfamilyBiochemistry, 2012
- Overexpression of a Chromatin Remodeling Factor, RSF-1/HBXAP, Correlates with Aggressive Oral Squamous Cell CarcinomaThe American Journal of Pathology, 2011
- Rsf-1, a Chromatin Remodeling Protein, Induces DNA Damage and Promotes Genomic InstabilityPublished by Elsevier BV ,2010
- Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single InstitutionAnnals of Surgical Oncology, 2010
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapyNature Genetics, 2010
- NF-κB- and C/EBPβ-driven Interleukin-1β Gene Expression and PAK1-mediated Caspase-1 Activation Play Essential Roles in Interleukin-1β Release from Helicobacter pylori Lipopolysaccharide-stimulated MacrophagesPublished by Elsevier BV ,2005
- HBXAP, a Novel PHD-Finger Protein, Possesses Transcription Repression ActivityGenomics, 2002
- Hepatitis B Virus pX Interacts with HBXAP, a PHD Finger Protein to Coactivate TranscriptionPublished by Elsevier BV ,2002